Summary
No FDA-label alignment can be assessed because the provided AI claims concern PMDA (Japan) search workflows for Sutent/generic listings, while the supplied FDA prescribing information excerpt relates only to hepatotoxicity warnings/monitoring/dosage modifications and does not support or evaluate PMDA search statements.
Category Scores
Accurate Statements
Unsupported Statements
In Japan, a PMDA search portal can be used to check products and listings related to generic “Sutent” (sunitinib).
The supplied FDA prescribing information excerpts do not address PMDA portals or any Japan regulatory search workflow.
PMDA search can be performed using the brand name “Sutent” and the active ingredient “sunitinib.”
Not supported by the provided FDA label excerpts.
PMDA search results may include entries labeled as generic or “後発医薬品” (pharmaceutical generics).
Not addressed in the provided FDA label excerpts.
A workflow for PMDA searching includes searching for “Sutent” and, if results are mostly branded-only, searching for the INN “sunitinib.”
Not supported by the provided FDA label excerpts.
PMDA results can be organized by applicant/approval category, and brand-name searches may miss generic entries unless searching by the generic substance name.
Not supported by the provided FDA label excerpts.
In a relevant PMDA generic result, the active ingredient listed should be sunitinib.
The FDA label excerpts provided do not include PMDA listing content or how PMDA results display active ingredients.
In a relevant PMDA generic result, dosage form/strength should be checked to match the same formulation as the intended Sutent.
The provided FDA excerpts are about hepatotoxicity/monitoring and do not provide guidance about PMDA search result verification or matching formulations.
In a relevant PMDA generic result, generic classification (generic/pharmaceutical generic vs innovator) should be checked.
Not addressed in the provided FDA label excerpts.
In a relevant PMDA generic result, application/approval dates or revision timeline may be shown.
Not addressed in the provided FDA label excerpts.
Sutent exists in specific strengths and formulations.
The provided FDA excerpts do not specify available strengths/formulations.
In PMDA results for multiple generics, matching by strength (e.g., mg) can help identify the correct dose/formulation.
Not addressed in the provided FDA excerpts.
In PMDA results for multiple generics, matching by dosage form (e.g., capsules) can help identify the correct formulation.
Not addressed in the provided FDA excerpts.
In PMDA results for multiple generics, matching by manufacturer/applicant can help identify the correct formulation.
Not addressed in the provided FDA excerpts.
Contradictions
Important Omissions
No FDA-prescribing-information content (indications, dosing/administration, contraindications, boxed warnings, warnings/precautions beyond hepatotoxicity excerpt, interactions, adverse reactions, monitoring, storage/handling) is actually evaluated or reflected in the listed claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The claims are about a regulatory search workflow (PMDA) rather than direct patient treatment instructions. However, they are unsupported by the provided FDA label excerpts, preventing label-concordance assessment.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Not Aligned
Primary Issue
Provided claims are unrelated to the supplied FDA prescribing information excerpts and therefore cannot be confirmed as label-supported.
Suggested Improvement
Evaluate only claims that are explicitly about FDA label content (e.g., hepatotoxicity warning, monitoring, interruption/resume/discontinue by Grade) using the provided FDA sections, and remove or segregate regulatory-search workflow statements that are outside the scope of the FDA label excerpts.